gsk201307116k.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending July 2013
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--

 

 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
   
1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
 
GlaxoSmithKline Plc
2. Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
Yes
 
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.
 
 
 
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
 
 
An event changing the breakdown of voting rights
 
 
Other (please specify):
 
   
3. Full name of person(s) subject to the
notification obligation:
Legal & General Group Plc (L&G)
4. Full name of shareholder(s)
 (if different from 3.):
N/A
 
5. Date of the transaction and date on
which the threshold is crossed or
reached:
 
09 July 2013
6. Date on which issuer notified:
10 July 2013
7. Threshold(s) that is/are crossed or
reached:
 
L&G (Below 3%)

8. Notified details:
 
A: Voting rights attached to shares
Class/type of
shares
 
if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
 
Number
of shares
Number of voting
rights
% of  voting rights
Direct
Indirect
Direct
Indirect
Ordinary 25p
 207,246,143
 
(As on 17/08/2010)
Below 3%
 
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
 
Type of financial
instrument
 
Expiration
date
 
Exercise/
Conversion Period
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
 
% of voting
rights
         
 
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
 
Type of financial
instrument
 
 
Exercise price
 
Expiration date
 
Exercise/
Conversion period
 
Number of voting rights instrument refers to
 
 
% of voting rights
 
         
Nominal
Delta
   
 
Total (A+B+C)
Number of voting rights
Percentage of voting rights
 
Below 3%
 
 
 


 
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
Legal & General Group Plc (Direct and Indirect) (Group)
 
 
Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect)
 
 
Legal & General Investment Management Limited (Indirect) (LGIM)
 
 
Legal & General Group Plc (Direct) (L&G) ( Below 3% = LGAS, LGPL & PMC)
 
Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)
Legal & General Insurance Holdings Limited (Direct) (LGIH)
 
Legal & General Assurance (Pensions Management) Limited  (PMC)
Legal & General Assurance Society Limited  (LGAS & LGPL)
 
 
Legal & General Pensions Limited (Direct)  (LGPL)
 


 
 
 Proxy Voting:  
 
10. Name of the proxy holder:
 N/A
 
11. Number of voting rights proxy holder will cease
to hold:
 
N/A
 
12. Date on which proxy holder will cease to hold
voting rights:
 
 N/A
 13. Additional information:  Notification using the total voting rights figure of  4,909,366,589
 
14. Contact name:
 
Angela Hayter (LGIM)
 
15. Contact telephone number:
 
020 3124 3851
 

 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: July 11,  2013
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc